# Spain pharma reforms, generic uptake and pricing debate > Live situation record from CLSTR: https://clstr.news/situations/spain-pharmaceutical-copayment-and-hta-reforms > Updated: 2026-07-27T18:33:12.000Z. Sources: 36. Developments: 18. Spain’s health‑system reforms continue to reshape pharmaceutical financing and market access. The tiered co‑payment system introduced in May 2026 and the health‑technology‑assessment decree aligning review with EU HTA rules have reduced the median gap between EU authorisation and public funding to 474 days, with 76.5 % of the 221 EU‑authorised innovative medicines now reimbursed. A July report on generic, hybrid and biosimilar uptake showed biosimilars accounting for 81.5 % of packs in competitive markets, hospital biosimilar varieties expanding from 14 to 22 molecules and oncology biosimilars capturing over 90 % of that segment. Hospital pack volumes rose from 19.8 million to 31.4 million, while pharmacy dispensing increased markedly. Concurrently, the Council of Ministers enacted the Medicines and Medical Devices Law, replacing the 2015 framework and introducing a dynamic pricing model for off‑patent drugs, a definition of "strategic medicines" to safeguard supply, early‑access mechanisms for innovative treatments, stronger reporting obligations for manufacturers and distributors, and an independent evaluation system to protect the public‑health budget’s sustainability. The Spanish Association of Generic Medicines (AESEG) has warned that the draft Royal Decree on financing and price setting does not curb the continual erosion of generic prices, lacking an explicit cap on reductions and risking market entry and supply continuity. The association urges safeguards to prevent commercial unviability of essential medicines. ## Claims - AESEG warned that the draft Royal Decree on financing and pricing of medicines does not sufficiently stop price erosion of generic, mature, essential, or low‑price medicines. (corroborated by 3 sources) - The current reference price system creates continuous pressure on prices that may compromise the economic viability of some medicines, market operator continuity, and supply security. (corroborated by 3 sources) - The draft decree maintains a logic of successive and cumulative price reductions without clear safeguards. (corroborated by 3 sources) - The draft decree does not set an explicit maximum limit on the initial price cut; the impact analysis references a 40 % reduction but it is not incorporated into the text. (corroborated by 3 sources) - AESEG believes the omission could discourage new drug launches, reduce competitor entry, and weaken competition. (corroborated by 3 sources) ## Timeline ### 2026-07-27: Spain's AESEG warns new drug pricing decree fails to stop generic price erosion AESEG says Spain's draft drug‑pricing decree fails to stop price erosion of generics, lacking safeguards and a cap on cuts, risking market viability and supply. 3 sources. https://clstr.news/cluster/spains-aeseg-warns-new-drug-pricing-decree-fails-to-stop-generic-price-erosion ### 2026-07-21: Spain advances generic, hybrid and biosimilar drug adoption and pricing reforms Spain's health ministry reports rapid growth of generic, hybrid and biosimilar medicines, while a new law introduces dynamic pricing and supply safeguards to improve affordability and access. 3 sources. https://clstr.news/cluster/spain-advances-generic-hybrid-and-biosimilar-drug-adoption-and-pricing-reforms ### 2026-07-17: Spain's research budget cap criticised as insufficient amid new health funding rollout Spain's research funding faces criticism as a €700 million cap is deemed insufficient, while the Ministry allocates €45.3 million to health research contracts and grants. 2 sources. https://clstr.news/cluster/spains-research-budget-cap-criticised-as-insufficient-amid-new-health-funding-rollout ### 2026-07-13: Spain's Health Secretary Padilla backs infectious disease specialty Spain’s health secretary Javier Padilla pledged a new infectious‑disease specialty and highlighted reforms making the country attractive for biotech investment. 3 sources. https://clstr.news/cluster/spain-positioned-as-leading-hub-for-biopharma-research-and-production ### 2026-07-13: Spain's generic drug push and Horizon Scanning forecast aim to sustain health system Spain's health ministry stresses generic drugs for cost savings and access, while Farmaindustria's Horizon Scanning forecasts 172 upcoming therapies to aid system planning and sustainability. 2 sources. https://clstr.news/cluster/spains-generic-drug-push-and-horizon-scanning-forecast-aim-to-sustain-health-system ### 2026-07-10: Novartis Spain launches 'Lleva la Delantera' breast cancer awareness campaign Novartis Spain unveiled the 'Lleva la Delantera' campaign in Madrid, uniting patients, associations and doctors to provide information, support and empowerment for women with breast cancer. 4 sources. https://clstr.news/cluster/novartis-spain-launches-lleva-la-delantera-breast-cancer-awareness-campaign ### 2026-07-07: Spain's BioSim reports surge in oncology biosimilars BioSim's Horizon Scanning update highlights a wave of new oncology and immune‑mediated biosimilars, EU approvals and 96 Spanish clinical trials across 47 centres. 2 sources. https://clstr.news/cluster/spains-biosim-reports-surge-in-oncology-biosimilars ### 2026-07-03: Spain adds social‑value criteria to innovative drug assessments Spain's new health regulations will evaluate innovative medicines on clinical benefit and broader social value, including patient autonomy, reduced care costs and productivity gains. 2 sources. https://clstr.news/cluster/spain-adds-socialvalue-criteria-to-innovative-drug-assessments ### 2026-06-29: Spanish biotech firms win health innovation awards Spanish biotech firms Polar NanoPharma, Stablepharma and SmartBio Analytics win national awards for cancer nanomedicine, vaccine stability and bio‑analytical innovations, highlighting Spain's health‑tech growth 2 sources. https://clstr.news/cluster/spanish-biotech-firms-win-health-innovation-awards ### 2026-06-23: Spain cuts drug funding delays as European pharma investment yields sixfold returns Spain shortens drug funding delays by 70 days, while a European pharma study shows a six‑fold economic return on €11.7 bn investment, boosting health outcomes and productivity. 6 sources. https://clstr.news/cluster/european-pharmaceutical-innovation-yields-nearly-sixfold-economic-return ### 2026-06-23: Spain to keep real drug prices confidential and draft conditional financing rules Spain’s coalition parties seek to keep real drug prices secret amid a Supreme Court case, while a draft decree proposes conditional and provisional funding for new medicines to manage uncertainty and costs. 2 sources. https://clstr.news/cluster/spain-to-keep-real-drug-prices-confidential-and-draft-conditional-financing-rules ### 2026-06-18: Novartis positions Barcelona as global hub for biomedical innovation Novartis’ Barcelona Centres of Excellence employ 700 staff, blend AI with biotech, boost Spain’s pharma sector and support drug supply to 80+ countries. 5 sources. https://clstr.news/cluster/novartis-positions-barcelona-as-global-hub-for-biomedical-innovation ### 2026-06-18: Novartis launches ‘Lleva la Delantera’ breast cancer empowerment campaign in Spain Novartis, together with Spanish breast‑cancer groups, launched the ‘Lleva la Delantera’ campaign in Spain to empower patients, improve information, and support shared decision‑making amid 38,000 annual cases. 3 sources. https://clstr.news/cluster/novartis-launches-lleva-la-delantera-breast-cancer-empowerment-campaign-in-spain ### 2026-06-17: Spain's health innovation drive highlighted by Novartis Novartis highlights Spain's leading role in health innovation, with 962 clinical trials, €1.7 bn R&D spend and plans to cut patient wait times while addressing funding and bureaucratic hurdles. 6 sources. https://clstr.news/cluster/spains-health-innovation-drive-highlighted-by-novartis ### 2026-06-09: Spain launches health reforms on drug dispensing and tech assessment Spain enacted two health reforms: a decree overhauling drug dispensing and verification, and a new health‑technology assessment framework praised by Sanofi, Roche and Philips for greater transparency and value‑ 2 sources. https://clstr.news/cluster/spain-reforms-drug-dispensing-and-healthtechnology-assessment-frameworks ### 2026-06-03: Spain's health ministry drafts new drug pricing and funding rules Spain's health ministry proposes a draft law to include therapeutic, economic and social criteria in drug pricing and funding, while a Johnson & Johnson project highlights medicines as societal and economic le‑ 2 sources. https://clstr.news/cluster/spains-health-ministry-drafts-new-drug-pricing-and-funding-rules ### 2026-05-31: Spain approves new health technology assessment decree and revamps drug copayment system Spain's new health technology assessment decree creates a unified HTA system with a transition year, while a progressive drug‑copayment reform reduces patient costs and may add a list of high‑value medicines, c 2 sources. https://clstr.news/cluster/spain-approves-new-health-technology-assessment-decree-and-revamps-drug-copayment-system ### 2026-05-13: Spain introduces progressive pharmaceutical co‑payment tiers under new decree Spain's new decree adds income‑based tiers and caps to prescription drug co‑payments, costing €265 M. 7 sources. https://clstr.news/cluster/spain-introduces-progressive-pharmaceutical-copayment-tiers-under-new-decree --- Cite as: Spain pharma reforms, generic uptake and pricing debate. CLSTR, https://clstr.news/situations/spain-pharmaceutical-copayment-and-hta-reforms